人工心臓 製造者 Carmat's 未来 seen in 手渡すs of 核心 支援者s
By Michal Aleksandrowicz, Tim Hepher and Laura Lenkiewicz
PARIS, Sept 29 (Reuters) - Troubled 人工心臓 製造者 Carmat is 控訴，上告ing to 重要な 株主s led by Airbus to 投資する new 基金s to 避ける the 崩壊（する） of the 30-year-old 投機・賭ける dating 支援する to a chance 会合 between a French 外科医 and a ミサイル 有力者／大事業家.
株 in the French medtech 支持する／優勝者 急落するd 37% this week after it 警告するd it could run out of cash at the end of October に引き続いて 供給（する） 問題／発行するs, as it 活発に 調査するs "several 財政／金融ing 選択s".
Airbus is the largest 株主 after one of its own 創立者s - late industrialist ジーンズ-Luc Lagardere - コースを変えるd engineers specialising in precision ミサイル parts into a new 投機・賭ける with 目だつ heart 外科医 Alain Carpentier in 1993.
The company they created, whose 指名する is (1)偽造する／(2)徐々に進むd from the 開始 letters of Carpentier and Lagardere's Matra 弁護 商売／仕事, later went public and Airbus now owns 12%.
Carmat 大統領 Stephane Piat told Reuters the 参加 of 存在するing 株主s 含むing Airbus in any fundraising would send an important signal.
"This is the message which we are giving to our 存在するing 株主s: that we live thanks to them," he said.
"They are the ones who decide whether or not we 追求する and so they have the most important 役割 の中で our 株主s. We hope that (the 決定／判定勝ち（する）) will be 肯定的な".
基金ing 会談 are 現在進行中の, with the French 政府 aware of the 状況／情勢, sources said.
大統領 Emmanuel Macron has made health 科学（工学）技術 a 重要な part of a 旗艦 re-industrialisation roadmap for 2030 and the French 投機・賭ける is one of only a handful of companies developing 代案／選択肢 s to 心臓移植s まっただ中に a 不足 of 組織／臓器s.
Sources said Carmat, which had 24 million euros cash at 中央の-year, was looking to raise a total of around 100 million. The company has not 公表する／暴露するd 量s.
The 決定／判定勝ち（する） whether to keep 投資するing in the 会社／堅い is 推定する／予想するd to be one of the 即座の topics on the desk of new Airbus 財政／金融 director Thomas Toepfer.
"(Airbus) are important because they are the first 投資家 and co-創立者 and they have a 重要な 役割, and I believe that they are conscious of this and are responsible," Piat said.
Airbus said this week it had 投資するd 50 million euros in Carmat but did not 演説（する）／住所 whether it would spend more.
"It´s very challenging market 条件s to raise 公正，普通株主権 資本／首都 for healthcare 在庫／株s 現在／一般に," said Samir Devani, managing director of Rx 安全s, 公式文書，認めるing cash-燃やすing, smaller healthcare 会社／堅いs have underperformed the market this year.
U.S. STUDIES
Carmat's Aeson prosthetic heart is connected to a 殴打／砲列 and 監査役 carried in a pouch. 現在／一般に 13 people are fitted with the 装置 which costs some 90,000 euros to make.
It remained 不明瞭な what, if any, contingency 計画（する）s may be needed to continue to support them if Carmat fails to raise the 基金s it needs to 生き残る.
Carmat won European 是認 for "橋（渡しをする）-to-移植（する）" in 2020, meaning its 装置s can be fitted to people を待つing 移植（する）s. In December 2021, it 一時停止するd implants after 質 問題／発行するs and was （疑いを）晴らすd to 再開する in late 2022.
実現可能 熟考する／考慮するs are 進行中で in the 部隊d 明言する／公表するs, where it 計画（する）s to 適用する for FDA pre-market 是認 by end-2026.
Airbus has 示すd in the past that Carmat is 非，不，無-核心 while 与える／捧げるing to periodic cash calls. It most recently 投資するd 10 million euros in March 2022.
It continues to 投資する in other 医療の 研究, however. In June, Airbus said it was working with Zurich University on growing human tissue in space to 扱う／治療する 損失d 組織／臓器s.
Airbus's 12% Carmat 火刑／賭ける sits in the now 大部分は 活動停止中の Matra 弁護 部隊 相続するd from Lagardere.
In the past, that 商売／仕事 stood at the centre of some of フラン's most storied and 極度の慎重さを要する dealmaking 含むing ミサイル sales to Taiwan in 1992.
Now, Carmat is one of two holdings in the 部隊 where it is dwarfed by a 火刑／賭ける in ミサイルs 巨大（な） MBDA. Matra 弁護 paid a （株主への）配当 of 207 million euros to Airbus in 2022, filings show.
(報告（する）／憶測ing by Tim Hepher, Michal Aleksandrowicz and Laura Lenkiewicz, 付加 報告（する）／憶測ing by Stephanie Hamel and Josephine Mason; Editing by Elaine Hardcastle)
